American International Group, Inc. Prelude Therapeutics Inc Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.68 - $4.84 $171 - $309	-64 Reduced 0.87%	7,333 $34,000
Q4 2023 Feb 13, 2024	BUY	$1.69 - $4.37 $498 - $1,289	295 Added 4.15%	7,397 $31,000
Q3 2023 Nov 13, 2023	BUY	$2.74 - $4.79 $6,384 - $11,160	2,330 Added 48.83%	7,102 $21,000
Q2 2023 Aug 04, 2023	BUY	$4.45 - $8.12 $21,235 - $38,748	4,772 New	4,772 $21,000
Q2 2022 Aug 12, 2022	SELL	$4.0 - $7.55 $21,492 - $40,566	-5,373 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $2,608 - $4,997	-378 Reduced 6.57%	5,373 $37,000
Q4 2021 Feb 11, 2022	SELL	$11.89 - $31.74 $2,045 - $5,459	-172 Reduced 2.9%	5,751 $72,000
Q3 2021 Nov 12, 2021	SELL	$25.78 - $38.65 $3,634 - $5,449	-141 Reduced 2.33%	5,923 $185,000
Q2 2021 Aug 13, 2021	BUY	$28.63 - $44.3 $8,245 - $12,758	288 Added 4.99%	6,064 $174,000
Q1 2021 May 07, 2021	BUY	$39.27 - $91.68 $17,200 - $40,155	438 Added 8.21%	5,776 $250,000
Q4 2020 Feb 12, 2021	BUY	$28.81 - $88.94 $153,787 - $474,761	5,338 New	5,338 $382,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.